Market Overview
| Study Period | 2020 - 2031 |
|---|---|
| Forecast Data Period | 2026 - 2031 |
| Historical Data Period | 2020 - 2024 |
| Growth Rate | 7.58% CAGR |
| Market Concentration | Low |
Major Players *Disclaimer: Major Players sorted in no particular order Image © Â鶹ÊÓƵ. Reuse requires attribution under CC BY 4.0. | |
Australia Cardiovascular Devices Market Analysis by Â鶹ÊÓƵ
The Australia Cardiovascular Devices Market size is expected to register a CAGR of 7.58% during the forecast period (2026-2031).
- The major factors driving the market are rapid technological advancements, the rising burden of various cardiovascular diseases, and increased preference for minimally invasive procedures. Heart-related mortality is caused by the rising prevalence of heart disorders such as cardiomyopathy and stroke. The most common diseases in the world are those related to the cardiovascular system.
- According to the June 2024 updates from the Australian Institutes of Health and Welfare report, in 2023, Australians lost an estimated 666,000 years of healthy life (DALY) due to all forms of cardiovascular diseases (CVD), equivalent to 25.1 per 1,000 population. In addition, the same source stated that 146,000 coronary angiography procedures were reported for patients admitted to the hospital – 97,200 (67%) for males and 48,900 (33%) for females. Thus, the high burden of cardiovascular diseases is expected to contribute to market growth over the forecast period.
- Heart disease increases with age, which of all ages is expected to drive the demand for cardiovascular devices for the diagnosis and management of these diseases, thereby augmenting market growth. For instance, according to October 2023 data from the University of Sydney, by 2026, more than 22% of Australians will be aged over 65 years. Thus, the growing aging population in the country, which is prone to cardiovascular diseases, is expected to contribute to market growth over the forecast period.
- Moreover, government support, increasing product approvals, and research and development activities undertaken by key market players contribute to the market's growth. For instance, in March 2022, the Regional Ministerial Budget Statement 2022-23 indicated that the Australian government allocated USD 17.2 million over four years to operate five mobile health clinics that will provide consultations and diagnosis in various medical specialties, including cardiology in Queensland.
- Therefore, owing to the rising prevalence of cardiac diseases and technological advancements in cardiovascular diseases, the market studied is expected to witness growth during the forecast period. However, stringent regulatory policies and product recalls are potential impediments to market growth.
Note: Market size and forecast figures in this report are generated using Â鶹ÊÓƵ’s proprietary estimation framework, updated with the latest available data and insights as of 2026.
Australia Cardiovascular Devices Market Trends and Insights
Electrocardiogram (ECG) Segment is Expected to Witness Growth Over the Forecast Period
- The electrocardiogram (ECG) segment is expected to experience substantial growth in the market studied, primarily due to the rising incidence of cardiac complications, the surge in product launches, and the increasing technological advancements in ECGs. ECGs, also known as electrocardiographs, record the heart's electrical signals and are commonly used equipment in operating rooms and ambulances. Personal devices such as smartwatches also offer ECG monitoring. ECGs can detect irregular heart rhythms, blocked or narrowed arteries in the heart, previous heart attacks, and the functioning of certain heart disease treatments such as pacemakers.
- The growth of the segment is being further boosted by increasing product launches, partnerships, and acquisitions in the country. For instance, in October 2022, AccurKardia, a software company that provides clinical-grade, device-agnostic, automated electrocardiogram (ECG) analytics, announced it would collaborate with Mawi, a MedTech provider of medical-grade wearables in the cardiac space, to integrate its proprietary ECG analytics into Mawi’s cardiac monitoring watch.
- The Victor Chang Cardiac Research Institute and the Charles Perkins Centre at the University of Sydney are two industrial sponsors of the consortium conducting clinical trials for cardiovascular devices. Such collaborative initiatives are expected to encourage medical device research and development in Australia and accelerate the commercialization of cardiovascular devices developed through this R&D, ultimately boosting the segment's growth during the forecast period.
- Therefore, due to the increasing technological advancements in ECGs and the rise in product launches, the segment is anticipated to register significant growth over the forecast period.
Catheters Segment is Anticipated to Witness Growth in the Australian Cardiovascular Devices Market Over the Forecast Period
- The catheter segment is expected to hold a significant share of the market during the forecast period, driven by several factors, including the rising incidence of cardiac diseases, government initiatives, and technological advancements in cardiac catheters. For example, in February 2024, BiVACOR, a clinical-stage medical device company, announced that USD 13 million had been awarded from the Australian government’s Medical Research Future Fund (MRFF) grant through the Artificial Heart Frontiers Program (AHFP) to support BiVACOR’s total artificial heart program and future product enhancements. Government support for cardiovascular services is expected to increase demand for catheters and drive market growth.
- The growth of the catheter segment in Australia is also being fueled by increasing product launches, partnerships, acquisitions, and collaborations. For instance, in February 2022, Vantari VR, an Australian medical virtual reality company, partnered with an internationally renowned cardiologist to develop a Virtual Right Heart Catheter Course to revolutionize clinician training. Such developments are expected to further boost the growth of the country's catheter segment during the forecast period.
- Moreover, approvals and product launches of new cardiac catheters are expected to drive market growth. In August 2022, Millar Inc., a medical device manufacturer and OEM solutions partner, received approval from the Therapeutic Goods Administration (TGA) in Australia for its Mikro-Cath Pressure Catheter, a single-use pressure catheter designed for medical research and diagnostic purposes. These types of developments in cardiac catheters in Australia are expected to contribute to market growth during the forecast period.
- Therefore, with the increasing number of catheter product launches and the rising incidence of cardiac complications, the catheter segment in Australia is expected to witness significant growth over the forecast period.
Regulatory Landscape
Cardiovascular devices in Australia are regulated by the Therapeutic Goods Administration (TGA) through inclusion in the Australian Register of Therapeutic Goods (ARTG) under the Therapeutic Goods (Medical Devices) Regulations 2002. For boundary and combination products, the TGA uses a primary intended purpose approach, supported by factor-based assessments for complex combinations, which is particularly relevant for device-drug combination products and device systems supplied with medicinal or biological components.
Market access and reimbursement are linked to private health funding settings administered by the Australian Government Department of Health and Aged Care. The Private Health Insurance (Medical Devices and Human Tissue Products) Rules (No. 1) 2026 were registered on 19 February 2026, and the Prescribed List of Medical Devices and Human Tissue Products (formerly the Prostheses List) is updated three times each year (March, July, and November), with an update effective from 1 July 2026. Inclusion supports eligibility for private health insurance benefits for many implantable and procedural cardiovascular products.
Competitive Landscape
The cardiovascular devices market in Australia is fragmented due to the presence of multiple companies operating in the region. The competitive landscape includes an analysis of several international and local companies that hold significant market share and are well-known in the industry. Key players in the market include Abbott Laboratories, Boston Scientific Corporation, Cardinal Health Inc., Edwards Lifesciences, General Electric Company (GE Healthcare), W. L. Gore & Associates Inc., Medtronic PLC, Biotronik, Siemens Healthineers AG, Canon Medical Systems Corporation, and B. Braun SE.
Australia Cardiovascular Devices Industry Leaders
Abbott Laboratories
Boston Scientific Corporation
Medtronic PLC
B. Braun SE
Cardinal Health Inc.
- *Disclaimer: Major Players sorted in no particular order
Market Opportunities and Future Outlook
Structural heart and advanced rhythm management are focal opportunity areas in Australia, with visible late-stage clinical and funding activity. In November 2025, Anteris Technologies received approval to begin the global pivotal PARADIGM trial for its DurAVR transcatheter heart valve. In January 2026, the company completed a US$320 million capital raise, including a US$90 million strategic investment from Medtronic to support trial execution and manufacturing scale-up, which underscores active capital formation around next-generation TAVR and local manufacturing capability.
Device lifecycle management and supply resilience also create additional whitespace as hospitals balance utilization, cost control, and sustainability. In April 2026, Cardinal Health commenced operations at its medical device remanufacturing hub in Beresfield (Newcastle), its first such facility outside the United States, expanding domestic access to remanufactured single-use device supply models used in procedural areas. On the regulatory side, TGA reclassification settings for devices in direct contact with the heart or central circulatory system (high-risk, Class III) and the ARTG transition pathway extending to 1 July 2029 increase the emphasis on compliance readiness, clinical evidence generation, and portfolio prioritization for sponsors across high-risk cardiovascular categories.
Recent Industry Developments
- July 2026: Jenscare Scientific reported the first Australian clinical use of its LuX-Valve system for transcatheter tricuspid valve replacement (TTVR) by the Structural Heart Team at Epworth. The milestone expands the country’s exposure to newer structural heart interventions beyond aortic programs and raises competitive intensity in transcatheter valve therapy pathways.
- April 2026: EBR Systems received a Priority Review Determination from the Therapeutic Goods Administration (TGA) for its WiSE cardiac resynchronisation therapy (CRT) system, shortening the evaluation target timeline from 225 to about 150 working days. The decision increases near-term regulatory momentum for leadless and alternative CRT approaches in Australia and can accelerate hospital evaluation planning and tender engagement once ARTG outcomes are secured.
- February 2026: Abbott Medical Australia Pty Ltd obtained ARTG inclusion for the AVEIR AR 2 right atrial leadless pacemaker (Model LSP203A) on February 12, 2026. The approval strengthens Abbott’s position in leadless pacing in Australia and supports broader clinical adoption of multi-chamber leadless strategies alongside established transvenous CRM portfolios.
Research Methodology Framework and Report Scope
Market Definition and Coverage
For this study, the market covers cardiovascular devices used in Australia to diagnose, monitor, and treat heart and vascular conditions, with sizing expressed in USD at the device market level based on actual demand in Australian healthcare settings.
Scope exclusions: Consumer wellness wearables that are not used as medical devices are excluded from the market sizing.
Segmentation Overview
- By Device Type
- Diagnostic and Monitoring Devices
- Electrocardiogram (ECG)
- Remote Cardiac Monitoring
- Other Diagnostic and Monitoring Devices
- Therapeutic and Surgical Devices
- Cardiac Assist Devices
- Cardiac Rhythm Management Devices
- Catheters
- Grafts
- Heart Valves
- Stents
- Other Therapeutic and Surgical Devices
- Diagnostic and Monitoring Devices
Data Sources, Market Sizing, and Validation
Desk Research
Desk research was used to map the clinical demand pool and the supply availability in Australia before the model was built. We relied on public sources such as the Australian Institute of Health and Welfare for disease burden and care setting signals, the Australian Bureau of Statistics for population and age mix, and the Department of Health and Aged Care for policy and funding direction.
To ground product usage patterns, references were also taken from sources such as the Therapeutic Goods Administration for device registration context, peer reviewed cardiology and health economics journals for procedure and adoption trends, and selected hospital network publications and annual reports for service capacity indicators. Company filings and investor presentations were used to understand category mixes and typical pricing movement, and then a paid subscription for company financials and a paid patent database were selectively used to cross-check technology focus and revenue footprints. The sources listed here are illustrative only, and many other public documents were also reviewed for data collection, validation, and clarification.
Primary Interviews and Surveys
Primary work focused on interviews and structured surveys with hospital procurement teams, cath lab and cardiac surgery stakeholders, distributors, and service partners who support monitoring and interventional pathways. Coverage was kept Australia-wide so differences in public versus private purchasing and metro versus regional procedure mix could be captured, and then used to validate desk assumptions on utilization, pricing, and replacement cycles.
Distribution of primary research fieldwork respondents
| Company type | Respondent position | Region |
|---|---|---|
| Top tier: 36% | CXOs: 15% | |
| Mid tier: 46% | Functional/Unit leaders: 27% | |
| Smaller Players: 18% | Managers: 58% |
Market-Sizing & Forecasting
The core sizing starts with a top-down demand pool build based on Australia procedure volumes and patient management pathways, which are then converted into device demand using penetration and utilization rates for key cardiovascular interventions and monitoring use. We corroborate these totals with selective bottom-up approximations, such as sampled average selling prices multiplied by inferred unit volumes from channel checks, followed by supplier and distributor revenue sense checks to calibrate the final market value.
Inputs that materially move the model include cardiovascular disease prevalence and the aging population share, coronary and structural procedure counts, hospital cath lab and cardiac surgery capacity signals, replacement cycles for implantable and capital equipment, and price progression by device class (including the impact of tendering and product mix changes). For forecasting, scenario analysis is used because procedure growth, funding priorities, and adoption of newer techniques can shift category-level growth in different directions. Where unit data is incomplete, gaps are handled using proxy indicators from similar procedure settings and then re-tested with primary feedback before assumptions are locked.
Data Validation & Update Cycle
Outputs are validated through triangulation across independent signals, so the modeled value is checked against procedure-led demand math, observed pricing bands, and supplier-side revenue reality. Outliers are investigated through variance checks by device category and care setting, and then reviewed by a second analyst before sign-off, which helps reduce the risk of single-source bias.
The report is refreshed annually, and interim updates are triggered when material events occur, such as major reimbursement shifts, regulatory changes, or noticeable procedure pattern swings. Before delivery, the model and key assumptions are revisited again so clients receive the latest updated view for the current cycle.
Â鶹ÊÓƵ's Australia Cardiovascular Devices Market Size Versus Other Published Estimates
Published market sizes for Australia cardiovascular devices often do not match because the studies do not count the same things, and they also use different base years, pricing logic, and procedure assumptions. In practice, the largest swings usually come from what is included inside cardiovascular devices, how monitoring is treated, and whether values are built from demand signals or from broader healthcare spending splits.
Consumer wellness wearables that are not used as medical devices sit outside Â鶹ÊÓƵ's scope, and that single exclusion can move totals when other sources include broader heart health gadgets alongside regulated device sales. Other gaps come from how procedure volumes are updated (recent cath lab activity versus older averages), how average prices are escalated over time, and whether currency timing and inflation treatment are kept consistent across historical and forecast years.
Benchmark comparison
| Source | Market Size | Gaps in Research Methodology |
|---|---|---|
| Â鶹ÊÓƵ | USD 0.00 B (2024) | |
| Regional Consultancy A | USD 2.82 B (2024) | This figure appears to use a broader device and application frame, and the headline value can rise if adjacent heart health categories and wider end-user coverage are counted alongside regulated cardiovascular device sales. |
| Trade Journal B | USD 0.90 B (2024) | This estimate looks more conservative and may reflect a narrower definition that focuses on a subset of device classes or hospital-driven demand only, which can reduce the total when outpatient monitoring and related categories are not fully captured. |
Across the three numbers, the spread mainly comes from scope width and how demand signals are translated into value through pricing and utilization. By keeping inputs tied to procedure-led demand and re-checking pricing and replacement timing through interviews, the final figure stays traceable to clear steps that can be repeated as new Australia data points emerge.
Key Questions Answered in the Report
What is the current Australia Cardiovascular Devices Market size?
The Australia Cardiovascular Devices Market is projected to register a CAGR of 7.58% during the forecast period (2026-2031)
Who are the key players in Australia Cardiovascular Devices Market?
Abbott Laboratories, Boston Scientific Corporation, Medtronic PLC, B. Braun SE and Cardinal Health Inc. are the major companies operating in the Australia Cardiovascular Devices Market.
What years does this Australia Cardiovascular Devices Market cover?
The report covers the Australia Cardiovascular Devices Market historical market size for years: 2019, 2020, 2021, 2022, 2023, 2024 and 2025. The report also forecasts the Australia Cardiovascular Devices Market size for years: 2026, 2027, 2028, 2029, 2030 and 2031.
Page last updated on:
